Canada Markets close in 1 hr 21 mins

XORTX Therapeutics Inc. (XRX.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.5100-0.0800 (-13.56%)
As of 2:39PM EDT. Market open.
Full screen
Previous Close0.5900
Open0.5500
Bid0.5100 x 0
Ask0.5200 x 0
Day's Range0.5100 - 0.5500
52 Week Range0.0950 - 0.8500
Volume281,511
Avg. Volume1,029,676
Market Cap56.139M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    XORTX Therapeutics Reports Special Meeting Results

    CALGARY, Alberta, Sept. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s Special Meeting of Shareholders held earlier today (the “Meeting”). A total of 72,768,832 common shares of the Company were voted at the Meeting, representing approximately 66% of the total number of

  • GlobeNewswire

    XORTX Announces Grant of European Patent

    Patent Supporting Diabetic Nephropathy – XRx-225CALGARY, Alberta, Sept. 01, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biotechnology company focused on developing therapeutics for the treatment of progressive kidney disease, is pleased to advise that further to its press release of April 6, 2021 that announced the intention of grant, the Company has now received receipt of the patent grant “EPO National Stage of PCT International Appl

  • GlobeNewswire

    XORTX Announces New Clinical Advisory Board Member

    CALGARY, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the Company’s clinical advisory board, Dr. Charles Edelstein. Dr. Allen Davidoff stated, “The appointment of Dr. Edelstein to XORTX’s clinical advisory board will be important in the future development of our cl